BRIEF—First highly selective PI3Kδ inhibitor approved in China

Shanghai Yingli Pharmaceutical announced that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China for the treatment of relapsed/refractory follicular lymphoma (R/R FL) in patients who have received two or more prior systemic therapies.

The new drug administration (NDA) approval validates Yingli Pharma’s strong innovation capabilities and fulfills the company’s objectives to bring new treatment options to patients and their families.

Yingli Pharma has entered into strategic partnership with Jiangsu Hengrui Pharmaceuticals, a leading pharmaceutical company with well-established oncology sales and marketing network, to commercialize因他瑞® in China.